<DOC>
	<DOCNO>NCT00342082</DOCNO>
	<brief_summary>This collaborative investigation NIEHS , Duke University , University North Carolina ( UNC ) study red blood cell baby bear HIV-infected woman receive anti-retroviral treatment . Studies show newborn mouse whose mother give anti-HIV medication pregnancy abnormal red blood cell circulate blood stream , indicate genetic damage cell cause anti-HIV medication . It know similar red blood cell abnormality develop human infant whose mother receive anti-HIV medication pregnancy . This study examine red blood cell infant expose anti-HIV medication non-exposed infant look difference involve specific genetic damage . Healthy pregnant woman HIV-infected pregnant woman receive antiretroviral treatment last trimester pregnancy labor may eligible study . Babies HIV-infected woman also include study . Candidates recruit medical center Duke University UNC . HIV-infected mother must plan baby follow either UNC Duke Pediatric Infectious Disease clinic . All woman study 1 milliliter ( le 1/2 teaspoon ) blood collect study delivery time blood sample obtain medical care . In addition , 5 ml ( 1 teaspoon ) umbilical cord blood also collect study time delivery cord longer attach baby . This conclude participation non-HIV infected woman . Babies born HIV-infected mother 1 ml blood drawn 0 3 day life , 4 6 week life , 4 6 month life . These bloodsamples collect time routine schedule blood draw .</brief_summary>
	<brief_title>Effects Anti-HIV Therapy Red Blood Cells HIV-infected Mothers Their Infants</brief_title>
	<detailed_description>This observational study pregnant woman newborn . The population include 10 HIV infected woman antiretroviral regimen newborn infant 10 healthy woman antiretroviral regimen newborn infant . Primary Objective : To determine micronucleated erythrocyte detect frequently cord blood infant expose zidovudine utero intrapartum compare cord blood infant expose . Secondary Objectives : - To determine micronucleated erythrocyte detect pregnant woman antiretrovial agent . - To determine micronucleated erythrocyte change frequency infant expose antiretrovial agent first 6 week life , time infant expose Zidovudine . - To determine change micronucleated erythrocytes infant cessation Zidovudine ( 6 month ) .</detailed_description>
	<criteria>INCLUSION CRITERIA : ( Treated Group ) HIVinfected Pregnant Treatment antiretroviral regimen INCLUSION CRITERIA : ( Control Group ) Healthy Pregnant Female EXCLUSION CRITERIA : ( Treated Group ) EXCLUSION CRITERIA : ( Control Group ) Delivery le 32 week gestation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 28, 2007</verification_date>
	<keyword>Zidovudine</keyword>
	<keyword>HIV</keyword>
	<keyword>Cord Blood</keyword>
</DOC>